Literature DB >> 22158250

GSK-3α/β kinases and amyloid production in vivo.

Tomasz Jaworski1, Ilse Dewachter, Benoit Lechat, Maarten Gees, Anna Kremer, David Demedts, Peter Borghgraef, Herman Devijver, Seb Kügler, Satish Patel, Jim R Woodgett, Fred Van Leuven.   

Abstract

Arising from C. J. Phiel, C. A. Wilson, V. M.-Y. Lee & P. S. Klein 423, 435-439 (2003)A major unresolved issue in Alzheimer's disease is identifying the mechanisms that regulate proteolytic processing of amyloid precursor protein (APP)-glycogen synthase kinase-3 (GSK-3) isozymes are thought to be important in this regulation. Phiel et al. proposed that GSK-3α, but not GSK-3β, controls production of amyloid. We analysed the proteolytic processing of mouse and human APP in mouse brain in vivo in five different genetic and viral models. Our data do not yield evidence for either GSK-3α-mediated or GSK-3β-mediated control of APP processing in brain in vivo.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22158250     DOI: 10.1038/nature10615

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  13 in total

1.  Early phenotypic changes in transgenic mice that overexpress different mutants of amyloid precursor protein in brain.

Authors:  D Moechars; I Dewachter; K Lorent; D Reversé; V Baekelandt; A Naidu; I Tesseur; K Spittaels; C V Haute; F Checler; E Godaux; B Cordell; F Van Leuven
Journal:  J Biol Chem       Date:  1999-03-05       Impact factor: 5.157

Review 2.  GSK-3 is essential in the pathogenesis of Alzheimer's disease.

Authors:  Akihiko Takashima
Journal:  J Alzheimers Dis       Date:  2006       Impact factor: 4.472

3.  Deficiency of presenilin-1 inhibits the normal cleavage of amyloid precursor protein.

Authors:  B De Strooper; P Saftig; K Craessaerts; H Vanderstichele; G Guhde; W Annaert; K Von Figura; F Van Leuven
Journal:  Nature       Date:  1998-01-22       Impact factor: 49.962

4.  Neuronal deficiency of presenilin 1 inhibits amyloid plaque formation and corrects hippocampal long-term potentiation but not a cognitive defect of amyloid precursor protein [V717I] transgenic mice.

Authors:  Ilse Dewachter; Delphine Reversé; Nathalie Caluwaerts; Laurence Ris; Cuno Kuipéri; Chris Van den Haute; Kurt Spittaels; Lieve Umans; Lutgarde Serneels; Els Thiry; Dieder Moechars; Mark Mercken; Emile Godaux; Fred Van Leuven
Journal:  J Neurosci       Date:  2002-05-01       Impact factor: 6.167

5.  Glycogen synthase kinase 3 beta is identical to tau protein kinase I generating several epitopes of paired helical filaments.

Authors:  K Ishiguro; A Shiratsuchi; S Sato; A Omori; M Arioka; S Kobayashi; T Uchida; K Imahori
Journal:  FEBS Lett       Date:  1993-07-05       Impact factor: 4.124

6.  Pathological Hallmarks, Clinical Parallels, and Value for Drug Testing in Alzheimer's Disease of the APP[V717I] London Transgenic Mouse Model.

Authors:  An Tanghe; Annelies Termont; Pascal Merchiers; Stephan Schilling; Hans-Ulrich Demuth; Louise Scrocchi; Fred Van Leuven; Gerard Griffioen; Tom Van Dooren
Journal:  Int J Alzheimers Dis       Date:  2010-09-02

7.  GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides.

Authors:  Christopher J Phiel; Christina A Wilson; Virginia M-Y Lee; Peter S Klein
Journal:  Nature       Date:  2003-05-22       Impact factor: 49.962

8.  Amyloid activates GSK-3beta to aggravate neuronal tauopathy in bigenic mice.

Authors:  Dick Terwel; David Muyllaert; Ilse Dewachter; Peter Borghgraef; Sophie Croes; Herman Devijver; Fred Van Leuven
Journal:  Am J Pathol       Date:  2008-02-07       Impact factor: 4.307

9.  AAV-tau mediates pyramidal neurodegeneration by cell-cycle re-entry without neurofibrillary tangle formation in wild-type mice.

Authors:  Tomasz Jaworski; Ilse Dewachter; Benoit Lechat; Sophie Croes; Annelies Termont; David Demedts; Peter Borghgraef; Herman Devijver; Robert K Filipkowski; Leszek Kaczmarek; Sebastian Kügler; Fred Van Leuven
Journal:  PLoS One       Date:  2009-10-01       Impact factor: 3.240

10.  Abnormalities in brain structure and behavior in GSK-3alpha mutant mice.

Authors:  Oksana Kaidanovich-Beilin; Tatiana V Lipina; Keizo Takao; Matthijs van Eede; Satoko Hattori; Christine Laliberté; Mustafa Khan; Kenichi Okamoto; John W Chambers; Paul J Fletcher; Katrina MacAulay; Bradley W Doble; Mark Henkelman; Tsuyoshi Miyakawa; John Roder; James R Woodgett
Journal:  Mol Brain       Date:  2009-11-19       Impact factor: 4.041

View more
  35 in total

1.  Selectively silencing GSK-3 isoforms reduces plaques and tangles in mouse models of Alzheimer's disease.

Authors:  David E Hurtado; Laura Molina-Porcel; Jenna C Carroll; Caryn Macdonald; Awo K Aboagye; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2012-05-23       Impact factor: 6.167

Review 2.  The cholinergic system in the pathophysiology and treatment of Alzheimer's disease.

Authors:  Harald Hampel; M-Marsel Mesulam; A Claudio Cuello; Martin R Farlow; Ezio Giacobini; George T Grossberg; Ara S Khachaturian; Andrea Vergallo; Enrica Cavedo; Peter J Snyder; Zaven S Khachaturian
Journal:  Brain       Date:  2018-07-01       Impact factor: 13.501

3.  BRI2 ectodomain affects Aβ42 fibrillation and tau truncation in human neuroblastoma cells.

Authors:  M Del Campo; C R Oliveira; W Scheper; R Zwart; C Korth; A Müller-Schiffmann; G Kostallas; H Biverstal; J Presto; J Johansson; J J Hoozemans; C F Pereira; C E Teunissen
Journal:  Cell Mol Life Sci       Date:  2014-10-22       Impact factor: 9.261

4.  A Chemical-Genetic Approach Reveals the Distinct Roles of GSK3α and GSK3β in Regulating Embryonic Stem Cell Fate.

Authors:  Xi Chen; Ruizhe Wang; Xu Liu; Yongming Wu; Tao Zhou; Yujia Yang; Andrew Perez; Ying-Chu Chen; Liang Hu; Jean Paul Chadarevian; Amir Assadieskandar; Chao Zhang; Qi-Long Ying
Journal:  Dev Cell       Date:  2017-12-04       Impact factor: 12.270

Review 5.  GSK3 in Alzheimer's disease: mind the isoforms.

Authors:  Tao Ma
Journal:  J Alzheimers Dis       Date:  2014       Impact factor: 4.472

6.  Polo-like kinase 2 phosphorylation of amyloid precursor protein regulates activity-dependent amyloidogenic processing.

Authors:  Yeunkum Lee; Ji Soo Lee; Kea Joo Lee; R Scott Turner; Hyang-Sook Hoe; Daniel T S Pak
Journal:  Neuropharmacology       Date:  2017-03-01       Impact factor: 5.250

Review 7.  Neurodegenerative aspects in vulnerability to schizophrenia spectrum disorders.

Authors:  Trevor Archer; Serafino Ricci; Danilo Garcia; Max Rapp Ricciardi
Journal:  Neurotox Res       Date:  2014-05-08       Impact factor: 3.911

8.  Inhibition of glycogen synthase kinase-3 ameliorates β-amyloid pathology and restores lysosomal acidification and mammalian target of rapamycin activity in the Alzheimer disease mouse model: in vivo and in vitro studies.

Authors:  Limor Avrahami; Dorit Farfara; Maya Shaham-Kol; Robert Vassar; Dan Frenkel; Hagit Eldar-Finkelman
Journal:  J Biol Chem       Date:  2012-11-15       Impact factor: 5.157

9.  Inhibition of GSK3β-mediated BACE1 expression reduces Alzheimer-associated phenotypes.

Authors:  Philip T T Ly; Yili Wu; Haiyan Zou; Ruitao Wang; Weihui Zhou; Ayae Kinoshita; Mingming Zhang; Yi Yang; Fang Cai; James Woodgett; Weihong Song
Journal:  J Clin Invest       Date:  2012-12-03       Impact factor: 14.808

Review 10.  The rise and fall of insulin signaling in Alzheimer's disease.

Authors:  B Chami; A J Steel; S M De La Monte; Greg T Sutherland
Journal:  Metab Brain Dis       Date:  2016-02-16       Impact factor: 3.584

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.